報價延遲最少15分鐘:2026/11/13 23:27 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.395 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.21/-0.45
|
|
企業價值
68.91M
|
| 資產負債 |
|
每股賬面淨值
0.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
409.66K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia. |
